Soo-bin Kim

Dr. Soo-bin Kim

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2021 in Toxins
Verified
Journal Article
Open access
PDF file
SKSoo-bin Kim
Soo-bin Kim
Hyoung Moon KimHyoung Moon Kim
Hyoung Moon Kim
HAHaeryun Ahn
Haeryun Ahn
YCYou-Jin Choi
You-Jin Choi
KHKyung-Seok Hu
Kyung-Seok Hu
Hee-Jin KimHee-Jin Kim
Hee-Jin Kim
When botulinum neurotoxin (BoNT) is injected to treat glabellar frown lines, the corrugator supercilia muscle (CSM) and procerus muscles are the main targets. Although there have been many studies on the treatment of glabellar frown lines, no study has confirmed the dynamic movement under ultrasonography (US). This study examined and evaluated dynamic muscle movements under US, thereby providing more effective BoNT injection guidelines for glabellar frowning. Glabellar frowning was categorized as either Type A or B. Type A is the general frowning pattern in which vertical wrinkles are made by contracting the CSM and procerus muscles (81%, n = 13). On US images, the procerus muscle thickens and the bilateral CSMs contract. Type B is an upward frowning pattern demonstrating upward elevation of vertical wrinkles due to hyperactive contraction of the frontalis muscle during frowning (19%, n = 3). On US images, the hypoechoic frontalis muscle thickens, forming horizontal forehead lines. After BoNT injection into the CSM and frontalis muscle but not the procerus muscle, Type B patterns showed improvements in the vertical crease and horizontal forehead line. Both types showed improvement in glabellar frown lines after conventional injection, but the horizontal forehead line did not improve in Type B. Type B wrinkles improved after additional injections into the frontalis muscle. This study provided novel anatomical findings related to the injection of glabellar frown lines with BoNT. Preliminary analysis and optimized procedures using US will enable more effective and safer injections.

20 June 2024 in Skin Research and Technology
Verified
Journal Article
Open access
SSSuk Bae Seo
Suk Bae Seo
JWJovian Wan
Jovian Wan
LCLisa Kwin Wah Chan
Lisa Kwin Wah Chan
KLKar Wai Alvin Lee
Kar Wai Alvin Lee
SKSoo-bin Kim
Soo-bin Kim
KYKyu-ho Yi
Kyu-ho Yi
Background: Acne vulgaris often results in permanent scars, with atrophic scars being the most common type and posing a significant therapeutic challenge due to their prevalence and impact on patients' quality of life. Various treatment options exist, including the use of poly‐ d,l ‐lactic acid delivered via different methods. Objective: This study aimed to assess the efficacy and safety of poly‐ d,l ‐lactic acid delivered via laser‐assisted needle‐free microjet injection for treating atrophic scars. Methods: Five Korean participants with atrophic facial scars were recruited. Poly‐ d,l ‐lactic acid solution was administered via the Mirajet system in five sessions, with clinical assessments conducted at baseline, before each session, and at 12‐week and 22‐week follow‐ups. Outcome measures included the Global Aesthetic Improvement Scale and patient satisfaction scores. Results: Positive results were observed at the 12‐week and 22‐week follow‐ups, with high patient satisfaction and improvements in atrophic scars and skin texture. Mild discomfort and transient side effects were reported, with no adverse events observed during the follow‐up period. Conclusion: Poly‐ d,l ‐lactic acid delivered by a laser‐assisted needle‐free microjet injector was judged to be effective for improving atrophic the facial area. Further research, particularly through randomized controlled trials, is needed to validate these findings and assess the longer‐term safety and sustainability of outcomes.

2 April 2024 in Skin Research and Technology
Verified
Journal Article
Open access
SSSuk Bae Seo
Suk Bae Seo
SKSoo-bin Kim
Soo-bin Kim
KYKyu-ho Yi
Kyu-ho Yi

27 March 2024 in Skin Research and Technology
Verified
Journal Article
Open access
JSJessica Jane Sy
Jessica Jane Sy
RWRaymond Wu
Raymond Wu
JWJovian Wan
Jovian Wan
SKSoo-bin Kim
Soo-bin Kim
KYKyu-ho Yi
Kyu-ho Yi
Background: Botulinum toxin injections are widely sought after in the field of medical aesthetics, offering consumers a variety of brand choices. Two commonly available botulinum toxin products, onabotulinumtoxinA and neubotulinumtoxinA, are featured in numerous clinics, leading many to question whether there are discernible differences in results, given their varying price ranges. Objective: To evaluate the efficacy and safety of neubotulinumtoxinA for the treatment of forehead horizontal lines. Methods: A 12‐week prospective, single‐centre, interventional split‐face study was conducted, including 30 subjects. These enrolled subjects received a single treatment session, with neubotulinumtoxinA applied to the left side of the forehead and onabotulinumtoxinA to the right side. A superficial injection was performed in all individuals, where the product was injected subdermally in the frontalis muscle. Evaluation was conducted at baseline, 7 days, 14, days and 4, 8, and 12 weeks after treatment, both when the eyebrows were at maximum lift and in a resting position. Treatment efficacy was assessed by two physicians and self‐assessed by the patients, using the Fitzpatrick Wrinkle Classification system. Adverse events were documented to evaluate safety. Results: The study found no statistically significant difference in the efficacy of neubotulinum and onabotulinum for treating forehead wrinkles, as indicated by p ‐values above 0.05 for both static and dynamic conditions. No safety and adverse events were observed in both formulations. Conclusion: This study has demonstrated that neither formulation is inferior to each other in the treatment of forehead horizontal lines.